Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy

Pembrolizumab is a cost-effective option for the first-line treatment of cisplatin-ineligible patients with PD-L1–positive locally advanced or metastatic urothelial carcinoma in Sweden, with potential quality-of-life and survival benefits compared to chemotherapy.